FDA-cleared profile

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.
FDA source Exact FDA submission Checked 2026-09-07
Intended users
Trained medical professionals using coronary CT analysis as part of physician diagnostic decision-making.
FDA source Exact FDA submission Checked 2026-09-07
Care setting and population
Cardiac CT/CCTA interpretation in cardiology or radiology practice.
FDA source Exact FDA submission Checked 2026-09-07
Workflow role
Web-based post-processing, coronary measurement and visualization, automated plaque and stenosis analysis, and structured report preparation for physician review.
FDA source Exact FDA submission Checked 2026-09-07
Required input
DICOM 3.0-compliant CCTA CT images obtained using any CT scanner for CAD or suspected CAD evaluation.
FDA source Exact FDA submission Checked 2026-09-07
Output and human action
Coronary-region extraction, suspected stenosis detection, plaque composition overlays, stenosis grading, vessel and lumen volumes, total, calcified, non-calcified and low-density plaque volumes, branch naming, stent and myocardial-bridge detection, and structured reports.
FDA source Exact FDA submission Checked 2026-09-07
Limitations
The software is not intended to replace qualified practitioner judgment and requires trained users. The reported agreement values are table-specific regulatory results, not a product-wide diagnostic sensitivity or clinical-outcome claim.
FDA source Exact FDA submission Checked 2026-09-07

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251656
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA
FDA source Exact FDA submission Checked 2026-09-07
Anatomy
Heart/Cardiovascular
FDA source Exact FDA submission Checked 2026-09-07
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-09-04
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The FDA summary describes a web application with DICOM CT input, transmission queues, image management, editing, and structured reports; local PACS, RIS, identity, routing, and report-ingestion behavior require testing.
FDA source Exact FDA submission Checked 2026-09-07
Deployment and data flow
K251656 describes a web-based application; public material reviewed does not establish hosting region, PHI flow, retention, availability, or site-specific service boundaries.
FDA source Exact FDA submission Checked 2026-09-07
Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-07

The reviewed exact FDA packet and Careverse family page do not establish a current scoped security attestation or deployed data-flow controls.

Training and support
The exact indication limits use to trained medical professionals who understand the software's functions, capabilities, and limitations.
FDA source Exact FDA submission Checked 2026-09-07
Monitoring and change control
Monitor eligible CCTA inputs, automated plaque and stenosis edits, report completeness, failed or repeated analyses, PACS/RIS delivery, reader overrides, turnaround, downtime, updates, complaints, and recalls by exact K251656 release.
FDA source Exact FDA submission Checked 2026-09-07

Buyer acceptance guidance derived from the exact FDA workflow and limitations.

Web-based coronary analysis

The exact submission is a web-based application for CCTA CT post-processing, coronary measurement, automated plaque and stenosis analysis, and structured reporting.

exact submission · checked 2026-09-07

Digital Heart family context

Careverse lists CoronaryDoc in its Digital Heart family alongside coronary FFR, calcium-score, cardiac-function, and plaque-analysis applications; the page presents family context rather than K251656 release documentation.

product family · checked 2026-09-07

Local interoperability acceptance

Test DICOM import, identity mapping, series selection, routing, structured-report delivery, user roles, edits, and failure recovery with the installed version before clinical use.

exact submission · checked 2026-09-07

This is buyer acceptance guidance based on the FDA-described workflow, not a verified interface contract.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
K251656 FDA evidence is a manufacturer-submitted regulatory agreement package for coronary stenosis and plaque outputs; the stored literature and trial candidate arrays were empty and no independent study was promoted.
FDA source Exact FDA submission Checked 2026-09-07
Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Severe stenosis exact-grade agreement

83.72 percent

Exact agreement with labeled severe-stenosis grade in K251656 stenosis-performance measurements labeled severe stenosis.

Tested version: Careverse CoronaryDoc configuration described in K251656

Non-stenosis exact-grade agreement

98.97 percent

Exact agreement with labeled non-stenosis grade in K251656 stenosis-performance measurements labeled non-stenosis.

Tested version: Careverse CoronaryDoc configuration described in K251656

Total plaque volume PCC

96.94 percent Pearson correlation coefficient

Correlation of total plaque volume with reference in K251656 plaque-performance measurements.

Tested version: Careverse CoronaryDoc configuration described in K251656

K251656 Careverse CoronaryDoc stenosis and plaque performance tables

Retrospective regulatory agreement testing against labeled/reference measurements across stenosis grades and plaque-volume outputs. · CCTA cardiac CT measurements for CAD or suspected CAD

exact submission · Tested version: Careverse CoronaryDoc configuration described in K251656 · Sponsor or vendor study

K251656

Measurement counts are reported by grade in the FDA table; unique patient and site counts are not promoted.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-07

No public list price or contract unit for K251656 was established in the reviewed official sources.

Reimbursement and coding
CMS LCD L39913 v7 and Article A59813 v6 provide conditional service-level policy context for AI-QCT/AI-CPA after completed and interpreted CCTA in WPS Medicare J5/J8 for selected symptomatic chest-pain patients; exact product/version eligibility and individual claim eligibility are not established.
Public source Product family Checked 2026-09-07

Service-level policy context; exact product/version and individual claim eligibility are not established. This is not a product code assignment, universal Medicare coverage determination, fee, or price.

75577

Conditional service-level coverage; product eligibility unconfirmed

Medicare / WPS · United States - WPS J5/J8 jurisdictions · Effective 2026-01-01

CMS policy context applies to an eligible CCTA plaque-analysis service in a limited WPS policy scope; it does not assign coverage to K251656 or establish individual claim eligibility.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The wave22 exact-submission recall query returned no native recall record for K251656. This does not establish absence of family, later-version, or adverse-event information.
Public source Exact FDA submission Checked 2026-09-07

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
12Source classes checked
0Reviewed PubMed leads
0Reviewed trial leads
0Unreviewed FDA recall leads

The stored PubMed and ClinicalTrials.gov candidate arrays were screened and were empty. No paper or trial was promoted; empty stored arrays do not establish that no external literature or trials exist. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, payer policy, fda device recall, literature index, trial registry, stored candidate metadata, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-07.

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and...

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K243859

PRAEVAorta®2

Nurea

PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images;...

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-08-29